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This is the largest series in Europe to report longer-term outcomes of endovascular thoracoabdominal aortic
aneurysm (TAAA) repair using fenestrated and branched stent grafts. Although endovascular TAAA repair in
expert hands is associated with high technical success rate, and remains safe and effective in the mid-term,
complications are not rare. Correct patient selection, careful planning, team effort, and technical success are
needed to provide the best possible outcome for the patients. The re-intervention rate is not low, but most re-
interventions can be performed by endovascular means.
Objective: To present a 10 year experience with endovascular thoracoabdominal aortic aneurysm (TAAA) repair
using fenestrated and branched stent grafts.
Materials and methods: Consecutive patients with TAAA treated with fenestrated and branched stent grafts
within the period January 2004eDecember 2013. Data were collected prospectively.
Results: 166 patients (125 male, 41 female, mean age 68.8  7.6 years) were treated. The mean TAAA diameter
was 71  9.3 mm. Types of TAAA were: type I, n ¼ 12 (7.2%), type II, n ¼ 50 (30.1%), type III, n ¼ 53 (31.9%),
type IV, n ¼ 41 (24.8%), and type V, n ¼ 10 (6%). Fifteen (9%) patients had an acute TAAA (11 contained rupture,
4 symptomatic). One hundred and eight (65%) patients were refused for open surgery earlier. Seventy eight
(47%) patients had previously undergone one or more open/endovascular aortic procedures. Technical success
was 95% (157/166). Thirty day operative mortality was 7.8% (13/166), with an in hospital mortality of 9% (15/
166). Peri-operative spinal cord ischemia (SCI) was observed in 15 patients (9%), including permanent paraplegia
in two (1.2%). Mean follow up was 29.2  21 months. During follow up 40 patients died, two of them probably
from aneurysm related cause. Re-intervention, mostly by endovascular means, was needed in 40 (24%) patients.
Estimated survival at 1, 2, and 5 years was 83%  3%, 78%  3.5%, and 66.6%  6.1%, respectively. Estimated
target vessel stent patency at 1, 2, and 5 years was 98%  0.6%, 97%  0.8%, and 94.2%  1.5%, respectively.
Estimated freedom from re-intervention at 1 and 3 years was 88.3%  2.7%, and 78.4%  4.5%, respectively.
Conclusions: Endovascular repair of TAAA with fenestrated and branched stent grafts in high volume centers
appears safe and effective in the mid-term in a high risk patient cohort. A considerable reintervention rate should
be acknowledged, however.
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Thoracoabdominal aortic aneurysms (TAAA) represent a
challenge for vascular surgeons. Conventional open repair
continues to be associated with remarkable mortality and
morbidity, despite improvements in intra- and post-
operative care.1 In 2003, a nationwide database from the
USA including 1542 patients reported in hospital post-operative mortality of 22.3% following elective TAAA open
repair. Even higher rates were observed for low volume
surgeons and hospitals.2 Post-operative morbidity is also
signiﬁcant, including respiratory insufﬁciency with pro-
longed ventilation, cardiac complications, and acute renal
failure.2 In addition, there is an inherent risk for paraplegia
depending on the extent of the aneurysm and its repair. InDOI of original article: http://dx.doi.org/10.1016/j.ejvs.2015.02.013
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ieved operative mortality rates of less than 10% with open
repair.3,4 Nevertheless, the composite adverse outcome,
deﬁned as operative death, renal failure requiring dialysis,
stroke, or paraplegia/paraparesis, remains high at 15.9%.3,4
Endovascular techniques have demonstrated short-term
advantages in abdominal aortic aneurysm (AAA) repair,
and have gradually evolved to address more complex AAA
and TAAA, using fenestrated and branched stent grafts.5e9
Early results of endovascular repair of TAAA in the ﬁrst 50
patients from the present study group have been published
previously.10 The present report discusses the 10 year
experience in 166 consecutive TAAA patients treated with
fenestrated and branched stent grafts.
MATERIALS AND METHODS
All consecutive patients with TAAA treated with fenestrated
or branched stent grafts under the guidance of the senior
author within the period January 2004eOctober 2009 at
one institution, and within the period November 2009e
December 2013 at a second institution, were included in
this study. Patients with post-dissection TAAA were also
included. Patients with suprarenal AAA treated with
fenestrated/branched grafts, even if including all four
visceral vessels, were excluded. Data were prospectively
collected. Endovascular repair as a technique was approved
by the institution’s ethical committee and all patients pro-
vided their informed consent.
Aneurysm morphology was assessed by thin cut
(1.5 mm) spiral computerized tomography angiography
(CTA) with axial and coronal reconstructions. The physical
status of all patients was assessed preoperatively with the
American Society of Anesthesiologists (ASA) score. The
indication for treatment was maximum aortic diameter
60 mm, except in the case of localized disease. Symp-
tomatic or ruptured TAAA were not excluded.
Stent grafts
Stent grafts were customized based on the Cook Zenith
system (William A. Cook Australia, Ltd., Brisbane, Australia),
ﬁtting fenestrations and/or branches for the visceral vessels
according to pre-operative CTA measurements. Three types
of stent grafts were used depending on the aortic anatomy
and aneurysm morphology: stent grafts with (A) fenestra-
tions only, (B) branches only, or (C) branches and fenes-
trations. The planning of fenestrations and branches was
based on the anatomy of the target vessels. Fenestrations
were preferred for right angle take off visceral arteries
(more common in renal arteries), and when the stent graft
body was against the aortic wall. Branches were preferen-
tially planned in larger aortic diameters, when the graft was
not against the aortic wall, and when the target vessels had
a downward path (often in the celiac artery).
The stent grafts had either a distal tube conﬁguration
when sealing could be achieved in the abdominal aorta (or
within the body of a pre-existing stent graft or surgical
graft), or a bifurcated conﬁguration, when landing in theiliac arteries. A proximal and distal sealing zone of at least
20 mm in length was always planned.
Procedure
The procedures were routinely performed either in an angio
suite with a ﬁxed imaging system (Artis Zee, Siemens,
Erlangen, Germany), or in a hybrid operating room with a
ﬁxed imaging system (Artis Zeego, Siemens, Erlangen, Ger-
many). The operation was always done under general
anesthesia. Peri-operative cerebrospinal ﬂuid (CSF) drainage
was selectively used to reduce the risk of paraplegia. Pa-
tients with TAAA type I, II, or III, and patients with previous
abdominal aortic surgery were routinely subjected to CSF
drainage.
Surgical access was performed via bilateral femoral cut
downs in case of stent grafts with fenestrations only, and
with an additional access from above (most commonly left
axillary artery cut down) in case of stent grafts with fen-
estrations and branches or branches only. The stent graft
deployment technique for fenestrated stent grafts has been
previously described in detail.11,12
For branched stent grafts, the branched component was
introduced through the femoral artery and positioned with
the distal edges of the branches 10e20 mm above the ostia
of the respective target vessels. After deployment of the
branched component, the large femoral sheath was
removed, and the arteriotomies temporarily closed (over
the stiff guidewire), using snuggers ﬁtted in purse string
sutures as previously described.12 This allowed for the
prompt restoration of blood ﬂow to the pelvis and lower
limbs. Subsequently, a 45 cm 12F sheath and a coaxial
70 cm 8F or 55 cm 7F sheath were both advanced into the
stent graft via the access from above. Each branch and its
corresponding target vessel were sequentially catheterized,
wired, and stented with a balloon expandable or self
expanding covered bridging stent. For fenestrations,
balloon expandable Atrium Advanta V12 (Maquet Getinge
Group, Hudson, NH, USA) of 22 or 38 mm length were
routinely used. For branches, Atrium Advanta V12 of
59 mm were used whenever possible. When a longer
covered bridging stent was required, the Fluency (Bard,
Murray Hill, NJ, USA) 80 mm stent was used. In branches,
both Atrium Advanta V12 and Fluency covered bridging
stents were relined with a self expandable stent if there
was kinking.
For stent grafts with branches and fenestrations, the
fenestrations were usually completed ﬁrst and followed by
the branches as described above.
Technical success was deﬁned as successful deployment
of the stent grafts with absence of type I or III endoleak,
and patent target vessels. Secondary technical endpoints
were reported according to the reporting standards for
thoracic endovascular aortic repair (TEVAR) and included
procedure time, estimated blood loss, ﬂuoroscopy time,
contrast load, and hospital and intensive care unit (ICU)
length of stay.13 Aneurysm sac morphology changes during
follow up were classiﬁed as follows: aneurysm sac shrinkage
526 E.L.G. Verhoeven et al.(reduction in sac diameter >5 mm), no signiﬁcant change
(5 to þ5 mm), and aneurysm sac expansion (increase in
sac diameter >5 mm).13
Post-operative management
Post-operatively, patients were monitored with clinical and
laboratory examination including thoracic and abdominal X-
rays in standardized antero-posterior and oblique views as
reference prior to discharge. CTA controls were performed
at 1 month, 1 year, and annually thereafter, depending on
each patient’s characteristics. Suspicion of endoleak or
branch vessel malperfusion, was investigated by additional
DSA for further evaluation and possible reintervention.
Data analysis
SPSS for Windows (version 20.0; SPSS Inc, Chicago, IL, USA)
was used for statistical analysis. Variables are presented as
mean  standard deviation (SD) in case of normal distribu-
tion, andmedian plus range for skewed distribution. Analyzed
outcomes included technical success, operativemortality and
majormorbidity, late eventswith regard to target vessel stent
patency, re-intervention, endoleak, and death. Survival,
target vessel stent patency, and re-intervention during follow
upwere subjected to KaplaneMeier analysis. A p value of less
than .05 was considered statistically signiﬁcant. To evaluate
the effect of the learning curve, the technical success rate in
the ﬁrst 5 years (2004e2008, n¼ 21) was compared with the
last 5 years (2009e2013, n ¼ 145). To evaluate whether ASA
IV patients should receive endovascular repair of TAAA, the
early and latemortality of ASA IV patientswas comparedwith
that of patients scoring ASA III or less.
RESULTS
Patients
During the study period, 166 patients (125 male, 41 female,
mean age 68.8  7.6 years) were treated. Fig. 1 shows the
distribution over the years. Patient comorbidities and risk
factors are listed in Table 1. Nineteen (11.4%) patients were
classiﬁed as ASA IV, 120 (72.3%) as ASA III, and 27 (16.3%)
as ASA II. One hundred and eight (65%) patients had been
refused for open surgery. Seventy eight (47%) patients had
previously undergone one or more open and/or endovas-
cular aortic procedures. Fifteen (9%) patients had an acute
TAAA (11 contained rupture, 4 symptomatic).Figure 1. Number of patients treated per year.TAAA characteristics
Mean TAAA diameter was 71  9.3 mm. Types of TAAA
according to the modiﬁed Crawford classiﬁcation were: type
I, n ¼ 12 (7.2%), type II, n ¼ 50 (30.1%), type III, n ¼ 53
(31.9%), type IV, n ¼ 41 (24.8%), and type V, n ¼ 10 (6%).
Nineteen of the 50 type II TAAA were chronic post type B
dissection TAAA.
Fenestrated/branched stent graft conﬁguration
Planned coverage of the aorta from left subclavian artery
(LSA) to aortic bifurcation was up to 50% in 40 (24.1%) pa-
tients, up to 75% in 76 (45.8%) patients, and up to 100% in 50
(30.1%) patients. In 70 (42.2%) patients a stent graft with
fenestrations and branches was used, in 57 (34.4%) a stent
graft with branches only, and in 39 (23.5%) patients a stent
graft with fenestrations only. The mean number of branches/
fenestrations per patient was 3.6  0.8. The total number of
planned fenestrations/branches was 600.These included 326
branches (314 downward branches, 8 upward branches, and
4 inner downward branches) and 274 fenestrations. A total of
293 renal arteries, 166 superior mesenteric arteries (SMA),
134 celiac arteries, four left subclavian arteries (LSA), and
three left common carotid arteries were targeted.
Operative data
An approach from above was required in 128 (77.1%) pa-
tients (left axillary artery: n ¼ 117, left subclavian artery:
n ¼ 7, left brachial artery: n ¼ 3, left common carotid
Table 1. Pre-operative patient characteristics.
Variable Patients N (%)
CAD 106 (63.9)
LVEF <45% 35 (21.1)
Hypertension 130 (78.3)
PAD 72 (43.4)
COPD 97 (58.4)
Smoking (current or past) 119 (71.7)
Diabetes mellitus 13 (7.8)
Hypercholesterolemia 132 (79.5)
Serum Cr >100 mmol/L 71 (42.7)
Previous stroke/TIA 10 (6)
Previous aortic surgery 78 (47)
Hostile abdomen 56 (33.7)
ASA III 139 (83.7)
Previous aortic procedure 78 (47%)
Open abdominal aortic surgery 44 (26.5%)
Open thoracic aortic surgery 13 (7.8%)
TEVAR 11 (6.6%)
EVAR 6 (3.6%)
Open thoracic aortic surgery þ TEVAR 3 (1.8%)
Open abdominal aortic surgery þ TEVAR 1 (0.6%)
CAD ¼ coronary artery disease; PAD ¼ peripheral arterial disease;
COPD ¼ chronic obstructive pulmonary disease; TIA ¼ transient
ischemic attack; ASA ¼ American Society of Anesthesiologists;
LVEF ¼ left ventricular ejection fraction; TEVAR ¼ thoracic
endovascular aortic repair; EVAR ¼ endovascular abdominal
aortic aneurysm repair.
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applied in 120 (72.3%) patients.
Fifty-ﬁve (33.1%) procedures were performed with a ﬁxed
imaging system in an angio suite, and 108 (65.1%) in a
hybrid operating room with a ﬁxed imaging system. Three
(1.8%) procedures at the early stages of the study, which
would normally have been performed in an angio suite,
were performed in a conventional operating room with a
mobile C-arm, as an extra laparotomy was planned for
access.
Technical success
Technical success was achieved in 157 (95%) patients,
including 15 patients who required unplanned additional
intra-operative maneuvers (Table 2). Technical success was
85.7% for the period 2004e2008 and 95.9% for the period
2009e2013 (p ¼ .089). Technical failure occurred overall in
nine (5%) patients. In ﬁve patients, catheterization of a
single target vessel was not possible (4 renal arteries, 1
celiac artery). Of those, one renal artery was revascularized
with an ileo-renal vein bypass. In two patients, the bridging
stents were implanted too deeply in the renal arteries,
resulting in renal artery occlusion. In one patient with a
solitary functioning kidney a renal artery rupture occurred
because of protrusion of the bridging stent into a small
branch of the main renal artery. This was treated with an
additional covered stent, but resulted in kidney loss and
dialysis. In one patient, a distal graft component was
deployed wrongly, and had to be removed via laparotomy,
and the procedure aborted. The patient recovered well, but
refused a renewed attempt to ﬁnish the procedure. She
died from myocardial infarct 4 months after the procedure.
Secondary technical endpoints
Mean procedure time was 272  85 min. Median estimated
blood loss was 400 mL (range, 100e5000 mL). Median
ﬂuoroscopy time was 73 min (range 15e240 min), and
median contrast load 210 mL (range 80e500 mL). Median
hospital and ICU length of stay were 10 days (range 3e50
days) and 2 days (range 0e42 days), respectively.
Table 2. Unplanned additional intra-operative maneuvers to
achieve technical success.
Procedure type N (%)
Retrograde target vessel catheterizationa 7 (4.2)
Iliac covered stent due to iliac artery rupture
intra-operatively
2 (1.2)
Femoral artery reconstruction 2 (1.2)
Extra stent grafts because of migration of the
proximal aortic tube graft
1 (0.6)
Extra thoracic tube graft þ LSA chimney 1 (0.6)
Extra axillary access for renal artery fenestration
catheterizationb
1 (0.6)
Additional TEVAR for rupture 1 (0.6)
a Via retroperitoneal surgical approach or laparotomy.
b Wire loss from femoral access.Peri-operative mortality and morbidity
Thirty day operative mortality was 7.8% (13/166), including
one patient with a contained rupture. In hospital mortality
was 9% (15/166); causes are shown in Table 3. Thirty day
operative mortality was 15.8% (3/19) for ASA IV patients,
and 6.8% (10/147) for patients with ASA III or less (p ¼ .17).
Major peri-operative complications are shown in Table 4.
Early re-intervention (30 days) was required in 12
(7.2%) patients. These included access artery revision for
ischemia or bleeding (n ¼ 7), coil embolization for bleeding
(n ¼ 2; 1 SMA branch, 1 renal artery branch), surgical
wound dehiscence repair (n ¼ 1), mesenteric hematoma
evacuation via laparotomy (n ¼ 1), and proximal thoracic
stent grafting because of retrograde dissection (n ¼ 1).
Table 3. Thirty day and in hospital mortality.
Cause of death N (%) Time of death
(postop day)
Multiple organ failure 6 (3.6) 1, 2, 5, 8, 9, 68
Intra-operative thoracic aortic rupture 1 (0.6) 1
Acute gastrointestinal bleeding 1 (0.6) 6
Paraplegia, colon ischemia/
colectomy/cardiac complications
1 (0.6) 6
Cardiac tamponade 1 (0.6) Operation day
Subdural hematoma complications
after CSF drainage removal
1 (0.6) 30
Peri-operative stroke complications 1 (0.6) 17
Pulmonary embolism 1 (0.6) 10
Respiratory insufﬁciency with
prolonged ICU stay
1 (0.6) 42
Mesenteric ischemia and
mesenteric bleeding
1 (0.6) Operation day
Table 4. Summary of major peri-operative complications.
Peri-operative complication N (%)
Cardiac complications (MI, arrythmias) 9 (5.4)
Pulmonary insufﬁciency 6 (3.6)
Renal function deterioration (>30% from
baseline)
9 (5.4)
Spinal cord ischemia (SCI) 15 (9)
Permanent paraplegia 2 (1.2)
Temporary paraparesis/paresthesia/urinary
incontinence
10 (6)
Permanent paraparesis/paresthesia/urinary
incontinence
3 (1.8)
Stroke 2 (1.2)
CSF leakage 1 (0.6)
Bleeding complications 7 (4.2)
Retroperitoneal hematoma 4 (2.4)
Mesenteric hematoma 2 (1.2)
Renal hematoma 2 (1.2)
Access site hematoma requiring revision 1 (0.6)
Colon ischemia 2 (1.2)
Lower extremity ischemia 2 (1.2)
Upper extremity ischemia 4 (2.4)
Brachial nerve injury 1 (0.6)
Groin infection 1 (0.6)
Surgical wound dehiscence 1 (0.6)
Retrograde dissection 1 (0.6)
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Mean follow up was 29.2  21 months. During follow up 40
patients died. One patient died most probably because of
stent graft complications (aorto-esophageal ﬁstula).
Another patient with a type IV TAAA died 4 months after
the procedure, after being treated for stent graft infection
by laparotomy, lavage, and omentoplasty. The remaining
patients died of unrelated causes. There was no aneurysm
rupture during follow up. Mortality during follow up was
signiﬁcantly higher in ASA IV patients compared with pa-
tients with ASA III or less (56.3% vs. 22.6%, p ¼ .02). Esti-
mated survival at 1, 2, and 5 years was 83%  3%,
78%  3.5%, and 66.6%  6.1%, respectively (Fig. 2A).
Aneurysm sac shrinkage was noted in 69%, no signiﬁcant
change was seen in 26%, and thee was aneurysm sac
expansion in 5% of the patients. Estimated freedom from
aneurysm sac expansion is shown in Fig. 2B.
During follow up 22 target vessels occluded, including 15
renal arteries, six coeliac arteries, and one SMA. Renal ar-
tery occlusion resulted in permanent dialysis in three pa-
tients (2 bilateral renal artery occlusions, 1 solitary kidney).
All coeliac artery and SMA occlusions were asymptomatic.
Estimated target vessel stent patency at 1, 2, and 5 years
was 98%  0.6%, 97%  0.8%, and 94.2%  1.5%,
respectively (Fig. 2C).
Late re-intervention (>30 days) was required in 28 pa-
tients with a total of 36 events (Table 5). Estimated freedom
from re-intervention at 1 and 3 years was 88.3%  2.7%,
and 78.4%  4.5%, respectively (Fig. 2D).
Endoleaks were detected in 33 patients. There were 20
type I/III endoleaks, including three type Ia, 11 type Ib
(target vessel; n ¼ 7, iliac; n ¼ 4), and six type III (target
vessel; n ¼ 4, aortic graft; n ¼ 2). There were 12 type II
endoleaks, three of which were treated with coil emboli-
zation. Finally, there was one undetermined endoleak. All
type I and III endoleaks were treated with additonal stent
grafts.
DISCUSSION
Regardless of the treatment method and the use of
adjunctive strategies, TAAA repair will continue to be
associated with a considerable mortality and morbidity.
Conventional TAAA by surgical repair is only applicable to a
selected group of patients, as shown in the high rejection
rate in the present cohort. Hybrid repair was initially
promising for a number of patients who could not tolerate
open repair, but has only limited advantages, as it is still a
major procedure.14e16 The use of total endovascular repair
has the potential for minimizing the surgical impact on the
patient, and allowing treatment of more suitable patients,
with promising results.7,9,10,17e20 Over the years, more
difﬁcult anatomies and sicker patients have been treated,
which probably explains a number of technical failures and
the relatively high mortality/morbidity in this series.
Nevertheless, the results of this 10 year experience with
endovascular TAAA repair are promising. Technical success
was high (95%), showing that total endovascular repair ofTAAA can be successfully completed in a high proportion of
patients. Most technical failures were ‘physician failures’
and most (89%) concerned target vessel catheterization/
stenting. Technical failures were most commonly observed
during the ﬁrst years of the program. Better pre-operative
stent graft planning and avoidance of intra-operative
“mistakes” with increasing experience has improved the
technical success rate over the last 5 years.
The 30 day operative mortality rate of 7.8%, with an in
hospital mortality of 9%, is not appealing for a real
“minimally invasive” technique. The impact of the disease
and the high risk proﬁle of the patient cohort (84% ASA
III/IV, 65% refused for open surgery, 23%  75 years old)
explain these ﬁgures. Almost half (47%) of the patients
had previous aortic surgery, which increased the technical
and clinical challenges associated with the repair. Finally,
the learning curve has to be taken into account, and it
required some time to implement a team approach
including an experienced anesthetist, an interventional
scrub nurse, a radiology technician, and at least two
experienced operators. Recently, a group from Lille pre-
sented their experience with endovascular TAAA repair in
89 patients, reporting similar peri-operative mortality
rates (30 day and in hospital mortality of 8.9% and 10%,
respectively).
Peri-operative morbidity was not negligible, but lower if
compared with open surgery. Cardiac peri-operative com-
plications of 5.4%, pulmonary complications of 3.6%, and
severe (>30%) renal function deterioration of 5.4%, with
dialysis in only one (0.6%) patient compare favorably with
reported open surgery results of large volume centers.
Recently, Coselli et al. reported cardiac peri-operative
complications in 30.4%, pulmonary complications in
41.1%, and deterioration of renal function requiring tem-
porary or permanent dialysis in 7.4%, from a total of 823
open TAAA repairs within the period 2005e2012.4
Peri-operative SCI developed in 15 (9%) patients, with
permanent paraplegia in two (1.2%). This rate is in line with
other contemporary endovascular series.7,18,20 To reduce
the incidence and impact of SCI, aggressive pre-operative,
intra-operative, and post-operative management has been
adopted. Stent graft planning aims to routinely maintain
LSA and bilateral hypogastric artery perfusion whenever
possible. CSF drainage is usually performed in type I, II, and
III TAAA, and in patients with previous abdominal aortic
surgery. Patients are kept normotensive throughout and
after the procedure. Finally, the procedure is performed via
open surgical access with the use of purse string sutures to
enable quick removal of large sheaths and re-establishment
of hypogastric and lower limb circulation as soon as
possible. This allows for more collateral circulation to the
spinal cord immediately, and reduces the impact of reper-
fusion injury later.
Late estimated survival is similar to other large endo-
vascular TAAA repair series, but could improve with stricter
selection of patients.9,20 In this series, 19 ASA IV patients
were treated. Both operative and late mortality in this small
group were higher compared with patients scoring ASA III
Figure 2. KaplaneMeier estimate of the cumulative overall patient survival (A), freedom of aneurysm sac expansion (B), target vessel stent
patency (C), and freedom of late re-interventions (D).
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tiary referrals and pre-conditioned patients. The approach
towards ASA IV patients has nevertheless become stricter,
as these patients only rarely seem to beneﬁt from this
procedure. On the other hand, it is believed that “healthy”
TAAA patients should be considered for endovascular TAAArepair, especially those with suitable anatomy and without
connective tissue disease.
The need for late re-intervention appears to be a concern
after total endovascular TAAA repair. In this series 17% of
the patients required at least one re-intervention within 2
to 3 years of the index procedure. Nevertheless, the
530 E.L.G. Verhoeven et al.majority (>85%) of re-interventions involved minimally
invasive endovascular procedures with a high technical
success rate (94%). Most of late re-interventions involved
correction of the stented visceral vessels either because of
endoleak (more common) or, rarely, because of stenosis.
This increased tendency for visceral vessel revision may be
partly because of the lack of dedicated bridging stent grafts
and other ancillary products. Despite the frequent need for
re-intervention, the technique seems to work well in terms
of target vessel stent patency, remaining around 95% for up
to 5 years.
Limitations of the present study include the constant
evolution of stent graft technology (both Cook branched
stent grafts and bridging covered stents), the learning curve,
and also the evolution of the technique in terms of treating
more difﬁcult anatomies and older and sicker patients.
CONCLUSIONS
Endovascular TAAA repair, planned and performed by
dedicated teams in high volume centers, provides high
technical success rates and low peri-operative mortality
and morbidity, given the impact of the disease and the
high risk proﬁle of the patients treated. The need for re-
intervention currently seems to represent the main
deﬁcit of the technique over open repair. Overall, mid-
term safety and durability as reﬂected by the absence of
late aneurysm rupture and target vessel stent patency is
excellent.
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Table 5. Late (>30 days) re-intervention events during follow up.
Re-intervention N
Target vessel bridging stent relining/extension 18
For endoleak 11
- Type Ib endoleak 7
- Type III endoleak 4
For stenosis 7
Iliac stent graft extension (Type Ib endoleak) 4
Proximal stent graft extension (Type Ia endoleak) 3
Coil embolization for Type II endoleak 3
Femoralefemoral crossover bypass 2
Thoracic bridging stent graft for disconnection
(Type III endoleak)
2
Target vessel thrombolysis 1
Groin drainage because of infected seroma 1
Laparotomyelavageeomentoplasty because of
stent graft infection
1
Ilio-renal bypass 1
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We report a case of a giant true brachial artery aneurysm
riovenous ﬁstula for haemodialysis. The ﬁstula had been ligat
Despite the huge size of the aneurysm (20  10  9 cm), t
symptoms. The aneurysm was surgically excluded and repla
brachial bypass. There were no post-operative or late complica
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531After Hemodialysis Fistula Closure
in a 61 year old patient with a previous radiocephalic arte-
ed 12 years previously after successful renal transplantation.
he patient did not complain of any compressive or ischemic
ced with a 6 cm expanded polytetraﬂuoroethylene brachio-
tions, and the graft was patent after 60 months of follow up.
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